- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02958696
Relative Bioavailability of HTL0018318 Oral Aqueous Solution Versus Capsules
February 2, 2017 updated by: Heptares Therapeutics Limited
A Phase 1, Randomised, Open Label, 2-period Crossover, Single Centre, 3-arm, Single Dose Study to Investigate the Relative Bioavailability of HTL0018318 Oral Aqueous Solution Versus Capsule Formation in Healthy Volunteers
HTL0018318 is a selective muscarinc M1 agonist.
This study is a phase I, open label, randomised, crossover, single dose, trial in healthy volunteers to compare the relative bioavailability of HTL0018318 when given by oral aqueous solution and in capsule formulation.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
37
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
London, United Kingdom, NW10 7EW
- Hammersmith Medicines Research
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 55 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Male or female healthy volunteer.
- Aged 18-55 years.
- A body mass index (Quetelet index) in the range 18.0-34.
- Sufficient intelligence to understand the nature of the trial and any hazards of participating in it. Ability to communicate satisfactorily with the investigator and to participate in, and comply with the requirements of, the entire trial.
- Willingness to comply with the contraception requirements of the trial.
- Willingness to give written consent to participate after reading the information and consent form, and after having the opportunity to discuss the trial with the investigator or his delegate.
- Willingness to give written consent to have data entered into The Overvolunteering Prevention System.
Exclusion Criteria:
- Clinically relevant abnormal history, physical findings, ECG, or laboratory values at the pre-trial screening assessment that could interfere with the objectives of the trial or the safety of the volunteer.
- QTcF outside range 300-450 msec for males, and 300-470 msec for females at resting ECG at screening and baseline.
- Family history of unexplained sudden death, or sudden death due to long QT syndrome.
- Clinically relevant abnormal findings based on 24 h ECG Holter monitoring during screening, including any of the following: > 200 ventricular ectopic heart beats, ventricular tachycardia, defined as >= 3 successive ventricular ectopic beats at a rate of >120 bpm, second degree heart block, sustained cardiac arrhythmias, including atrial fibrillation, complete heart block and supraventricular tachycardia (SVT), any symptomatic arrhythmia except isolated extra systoles.
- Aspartate transaminase (AST), alanine transaminase (ALT), gamma glutamyl transferase (GGT) or total bilirubin >1.5 x ULN at screening, or other laboratory blood chemistry test results outside the normal reference range unless deemed not clinically significant by the investigator.
- Clinically significant renal insufficiency as indicated by a glomerular filtration rate lower than the age-related L at screening. In the event of a glomerular filtration rate >80, eligibility may be confirmed by a second measurement.
- Blood pressure and heart rate in supine position at the screening examination outside the ranges 90-140 mm Hg systolic, 50-90 mm Hg diastolic; heart rate 45-100 beats/min. Subject with borderline values can be included if the values are deemed not clinically significant by the investigator.
- Presence of acute or chronic illness or history of chronic illness sufficient to invalidate the volunteer's participation in the trial or make it unnecessarily hazardous.
- Impaired gastrointestinal, endocrine, thyroid, hepatic, cardiovascular, respiratory, haematological, renal or neurological function, diabetes mellitus, coronary heart disease, or history of any psychotic mental illness deemed clinically significant by the investigator.
- History of a chronic respiratory condition, such as asthma, recurrent chest infections of chronic obstructive pulmonary disease.
- History of epilepsy or seizures.
- History of a severe allergy. Non-active hayfever is acceptable.
- Surgery (e.g. stomach bypass) or medical condition that might affect absorption, metabolism or elimination of medicines.
- Presence or history of severe adverse reaction to any drug.
- Woman who is pregnant or lactating, or pre-menopausal woman who is sexually active and not using a reliable method of contraception.
- Use of a prescription or over-the-counter medicine, or any herbal remedy or nutritional supplement, during the 21 days before the first dose of trial medication until the end of the study, with the exception of acetaminophen (paracetamol), hormonal contraceptives or hormone replacement therapy (HRT).
- Presence or history of drug or alcohol abuse in the last 5 years, or intake of more than 21 units of alcohol weekly (for men) or 14 units of alcohol weekly (for women), or use of cigarettes or nicotine-containing products during the 3 months before the first dose until the end of the study.
- Evidence of drug abuse on urine testing.
- Positive test for hepatitis B, hepatitis C or HIV.
- Positive test for alcohol or smoking before dosing.
- Participation in another clinical trial of a new chemical entity or a prescription medicine within the previous 3 months.
- Loss of more than 500 mL blood during the 3 months before the trial, eg as a blood donor.
- Possibility that the volunteer will not cooperate with the requirements of the protocol.
- Objection by General Practitioner (GP) to volunteer entering trial.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: HTL0018318 low dose
low dose aqueous solution and/or equivalent low dose capsule
|
Two single doses of active drug (low, mid or high dose either as aqueous solution or capsule) separated by a washout of at least 12 days.
|
Active Comparator: HTL0018318 mid dose
mid dose aqueous solution and/or equivalent mid dose capsule
|
Two single doses of active drug (low, mid or high dose either as aqueous solution or capsule) separated by a washout of at least 12 days.
|
Active Comparator: HTL0018318 high dose
high dose aqueous solution and/or equivalent high dose capsule(s)
|
Two single doses of active drug (low, mid or high dose either as aqueous solution or capsule) separated by a washout of at least 12 days.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Maximum plasma concentration (Cmax) of HTL0018318
Time Frame: Predose to 168h post dose
|
Comparison of bioavailability in plasma
|
Predose to 168h post dose
|
Area under the curve (AUC) of HTL0018318
Time Frame: Predose to 168h post dose
|
Comparison of bioavailability in plasma
|
Predose to 168h post dose
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Time to maximum concentration (tmax)
Time Frame: Predose to 168h post dose
|
Pharmacokinetics in plasma
|
Predose to 168h post dose
|
Half-life (t1/2)
Time Frame: Predose to 168h post dose
|
Pharmacokinetics in plasma
|
Predose to 168h post dose
|
Apparent volume of distribution (Vz/F)
Time Frame: Predose to 168h post dose
|
Pharmacokinetics in plasma
|
Predose to 168h post dose
|
Apparent clearance (CLp/F)
Time Frame: Predose to 168h post dose
|
Pharmacokinetics in plasma
|
Predose to 168h post dose
|
Amount excreted in urine (Ae)
Time Frame: Predose to 168h post dose
|
Pharmacokinetics in urine
|
Predose to 168h post dose
|
Fraction excreted in urine (fe/F)
Time Frame: Predose to 168h post dose
|
Pharmacokinetics in urine
|
Predose to 168h post dose
|
Clearance in urine (CLr)
Time Frame: Predose to 168h post dose
|
Pharmacokinetics in urine
|
Predose to 168h post dose
|
Treatment-emergent adverse events
Time Frame: Predose up to 28 days post dose
|
Adverse events
|
Predose up to 28 days post dose
|
Vital signs
Time Frame: Predose up to 28 days post dose
|
Heart rate and blood pressure
|
Predose up to 28 days post dose
|
Physical examinations
Time Frame: Predose up to 28 days post dose
|
Physical examinations
|
Predose up to 28 days post dose
|
Laboratory safety assessments
Time Frame: Predose up to 28 days post dose
|
Hematology
|
Predose up to 28 days post dose
|
ECG
Time Frame: Predose up to 28 days post dose
|
ECG
|
Predose up to 28 days post dose
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Adeep Puri, MPhil MBBS, Hammersmith Medicines Research
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
October 1, 2016
Primary Completion (Actual)
January 1, 2017
Study Completion (Actual)
January 1, 2017
Study Registration Dates
First Submitted
November 1, 2016
First Submitted That Met QC Criteria
November 4, 2016
First Posted (Estimate)
November 8, 2016
Study Record Updates
Last Update Posted (Estimate)
February 3, 2017
Last Update Submitted That Met QC Criteria
February 2, 2017
Last Verified
February 1, 2017
More Information
Terms related to this study
Other Study ID Numbers
- HTL0018318-104
- 16-024 (HMR Protocol Code)
- 2016-003313-99 (EudraCT Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Bioavailability and Pharmacokinetics
-
Xspray Pharma ABCompletedPharmacokinetics | BioavailabilityUnited Kingdom
-
Teva Branded Pharmaceutical Products R&D, Inc.Completed
-
AstraZenecaAcerta Pharma, LLCCompletedPharmacokinetics | BioavailabilityUnited States
-
Central Institute of Mental Health, MannheimTerminated
-
AstraZenecaCompletedPharmacokinetics | BioavailabilityUnited States
-
Cinclus Pharma AGCompletedPharmacokinetics | Bioavailability | SafetySlovenia
-
Endo PharmaceuticalsSFBC AnapharmCompletedPharmacokinetics | Bioavailability | AbsorptionCanada
-
PfizerCompletedSmoking Cessation | Pharmacokinetics | BioavailabilityUnited States
-
Labopharm Inc.CompletedHealthy Subjects | Pharmacokinetics | Bioavailability
-
Janssen Scientific Affairs, LLCBayerCompletedPharmacokinetics | Healthy Participants | BioavailabilityUnited States
Clinical Trials on HTL0018318
-
Heptares Therapeutics LimitedSoseiWithdrawnDementia With Lewy BodiesJapan
-
Heptares Therapeutics LimitedAllerganCompletedAlzheimer's DiseaseCzechia, Poland, Slovakia, Spain
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom